988 related articles for article (PubMed ID: 15269925)
1. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
2. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
3. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
Kind AH; Zakowski LJ; McBride PE
WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
[TBL] [Abstract][Full Text] [Related]
5. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
6. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
[TBL] [Abstract][Full Text] [Related]
7. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for statin-associated rhabdomyolysis.
Schech S; Graham D; Staffa J; Andrade SE; La Grenade L; Burgess M; Blough D; Stergachis A; Chan KA; Platt R; Shatin D
Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
11. [Antilipemic therapy and rhabdomyolysis].
Paragh G; Balogh Z; Romics L
Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.
Landesman KA; Stozek M; Freeman NJ
Conn Med; 1999 Aug; 63(8):455-7. PubMed ID: 10500341
[TBL] [Abstract][Full Text] [Related]
13. Fatal rhabdomyolysis caused by lipid-lowering therapy.
Federman DG; Hussain F; Walters AB
South Med J; 2001 Oct; 94(10):1023-6. PubMed ID: 11702815
[TBL] [Abstract][Full Text] [Related]
14. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
[TBL] [Abstract][Full Text] [Related]
15. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
[TBL] [Abstract][Full Text] [Related]
16. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
17. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
Koro CE; Sowell MO; Stender M; Qizilbash N
Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
[TBL] [Abstract][Full Text] [Related]
18. [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].
SantaCruz PL; González A; León ME; Fernández MY
Nefrologia; 2002; 22(3):301-2. PubMed ID: 12123135
[No Abstract] [Full Text] [Related]
19. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.
Marsà Carretero M; Alos Manrique C; Valles Callol JA
Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671
[No Abstract] [Full Text] [Related]
20. Statin safety: lessons from new drug applications for marketed statins.
Jacobson TA
Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
